Who makes remifentanil hydrochlorid?

remifentanil hydrochlorid is developed by Helsinki University Central Hospital.

What development phase is remifentanil hydrochlorid in?

remifentanil hydrochlorid is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

remifentanil hydrochlorid

Helsinki University Central Hospital · FDA-approved active Small molecule Quality 0/100

Remifentanil hydrochloride, marketed by Helsinki University Central Hospital, is an established anesthetic agent with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and strong patent protection. The primary risk is the potential for increased competition following the 2028 patent expiry.

At a glance

Generic name	remifentanil hydrochlorid
Also known as	-Ultiva
Sponsor	Helsinki University Central Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Patient-controlled Sedation With Propofol and Remifentanyl for Endoscopic Retrograde Cholangiopancreatography (ERCP) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

remifentanil hydrochlorid CI brief — competitive landscape report
remifentanil hydrochlorid updates RSS · CI watch RSS
Helsinki University Central Hospital portfolio CI